Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723255 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00723255: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00723255 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00723255, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This phase II trial is studying the side effects of giving bevacizumab together with temsirolimus and to see how well it works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving bevacizumab together with temsirolimus may kill more tumor cells.
Interventions
- BIOLOGICAL bevacizumab
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-09 |
| Est. Completion | 2016-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723255
The ClinicalTrials.gov registry entry for NCT00723255 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT00723255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00723255 about?
NCT00723255 is a clinical study titled "Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer". This phase II trial is studying the side effects of giving bevacizumab together with temsirolimus and to see how well it works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ab...
What is the current status of trial NCT00723255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2008-09. Estimated completion is 2016-01-25.
What interventions are being tested in trial NCT00723255?
The interventions under investigation include: bevacizumab (BIOLOGICAL), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00723255?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.